Semaglutide: Risks & Legal Status

Critical Safety Information#

Semaglutide (Ozempic/Wegovy/Rybelsus) is an FDA-approved prescription medication with well-characterized risks identified through extensive clinical trial programs (SUSTAIN, PIONEER, STEP, SELECT) enrolling over 25,000 participants and growing post-marketing surveillance since 2017. This page provides a comprehensive overview of known risks, the boxed warning, regulatory status, and population-specific warnings.

Boxed Warning: Thyroid C-Cell Tumors#

Semaglutide carries a boxed warning regarding the risk of thyroid C-cell tumors, shared with all GLP-1 receptor agonist class medications.

Preclinical Evidence#

In rodent carcinogenicity studies, semaglutide caused statistically significant, dose-dependent increases in thyroid C-cell tumors, including medullary thyroid carcinoma (MTC). This effect is consistent across the GLP-1 agonist class and is mediated by sustained GLP-1 receptor activation on rodent thyroid C-cells, which express high levels of GLP-1 receptors.

Relevance to Humans#

Human thyroid C-cells have substantially lower GLP-1 receptor expression compared to rodents. Epidemiologic data from over 8 years of GLP-1 agonist market experience (including exenatide, liraglutide, and semaglutide) have not demonstrated an increased incidence of MTC in humans. However, the long latency period of thyroid cancer means this risk cannot be definitively excluded.

Clinical Implications#

Semaglutide is contraindicated in patients with a personal or family history of MTC or MEN2. Patients should be counseled on thyroid tumor symptoms (neck mass, difficulty swallowing, shortness of breath, persistent hoarseness). Routine calcitonin monitoring is not recommended.

Pancreatitis Risk#

Acute pancreatitis has been reported with semaglutide and other GLP-1 receptor agonists. In clinical trials, the incidence was low (less than 0.5%), but cases can be severe or life-threatening. Patients should report persistent severe abdominal pain, and semaglutide should be discontinued if pancreatitis is suspected and not restarted if confirmed.

Gallbladder Disease#

Cholelithiasis and cholecystitis have been reported at higher rates with semaglutide than placebo, particularly in weight management trials where rapid weight loss occurs. In STEP trials, cholelithiasis was reported in approximately 1.6% of semaglutide patients versus 0.7% with placebo. Rapid weight loss from any cause increases gallstone risk through bile cholesterol supersaturation.

Diabetic Retinopathy Complications#

SUSTAIN-6 identified a significant increase in diabetic retinopathy complications with semaglutide (HR 1.76). This is attributed to the rapid improvement in glycemic control rather than a direct drug effect, consistent with the well-documented phenomenon of early worsening of retinopathy seen with intensive insulin therapy. Patients with pre-existing proliferative retinopathy or diabetic macular edema should undergo ophthalmologic evaluation before starting semaglutide.

Gastrointestinal Risks#

Beyond the common GI side effects, more serious complications have been identified:

• Intestinal obstruction and ileus: Rare post-marketing reports related to significant gastric emptying delay
• Gastroparesis concerns: Patients with pre-existing gastroparesis may experience worsening with semaglutide
• Anesthesia considerations: Delayed gastric emptying may increase aspiration risk during procedures requiring sedation. Patients may need to hold semaglutide before elective surgery

Acute Kidney Injury#

AKI has been reported with semaglutide, typically secondary to dehydration from GI adverse events. Patients with pre-existing renal impairment are at higher risk. Adequate hydration should be emphasized, and renal function monitored during episodes of significant GI symptoms.

Suicidal Ideation#

Post-marketing surveillance has identified reports of suicidal ideation with GLP-1 agonists. The FDA concluded in 2025 that available evidence does not establish causation, but monitoring continues. Patients with psychiatric history should be monitored for mood changes.

Regulatory and Legal Status#

Semaglutide is a prescription medication in all jurisdictions where approved. It is not a controlled substance.

At-Risk Populations#

Patients with MTC or MEN2 History#

Absolute contraindication due to the thyroid C-cell tumor boxed warning.

Pregnant and Breastfeeding Women#

Semaglutide should not be used during pregnancy. Animal studies showed adverse developmental effects. Due to the approximately 7-day half-life, discontinue at least 2 months before planned pregnancy. It is unknown whether semaglutide is excreted in breast milk.

Patients Undergoing Surgery#

Due to gastric emptying delay, patients should discuss semaglutide management with their surgical team before elective procedures requiring general anesthesia.

Risk Mitigation#

For Prescribers#

1. Screen for MTC/MEN2 history before prescribing
2. Assess history of pancreatitis and gallbladder disease
3. Evaluate diabetic retinopathy status before initiation
4. Reduce insulin or sulfonylurea doses when adding semaglutide
5. Counsel on GI management and hydration
6. Screen for psychiatric history

For Patients#

1. Follow dose escalation schedule to minimize GI side effects
2. Report persistent severe abdominal pain immediately
3. Report neck lumps, difficulty swallowing, or persistent hoarseness
4. Maintain adequate hydration, especially during nausea or vomiting
5. Inform healthcare providers about semaglutide before any surgery
6. Use effective contraception; discontinue at least 2 months before planned pregnancy

Related Reading#

• Semaglutide overview and research guide
• Semaglutide side effects profile
• Semaglutide research evidence